Subscribe

ASH 2015 - Castleman’s Disease, Lymphoma, and CLL

Results of the planned analysis of health-related quality-of-life and fatigue outcomes in the randomized, placebo-controlled, phase 3 HELIOS trial that evaluated the Bruton’s tyrosine kinase inhibitor ibrutinib plus bendamustine/rituximab compared with bendamustine/rituximab in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) were presented.
De Vos and colleagues reported results of an ongoing phase 1, open-label, dose-escalation study of venetoclax, an oral inhibitor of the antiapoptotic protein BCL-2 in combination with bendamustine/rituximab in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).
The updated safety and efficacy results of a phase 1 dose-escalation study of venetoclax, an oral inhibitor of the antiapoptotic protein BCL-2, in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) were reported.
Ribrag and colleagues reported results of a phase 2 study of the oral histone deacetylase inhibitor abexinostat in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL).
Chanan-Khan and colleagues reported on the overall safety and management of adverse events with Bruton’s tyrosine kinase inhibitor ibrutinib therapy in comparison to placebo treatment in the randomized, double-blind, placebo-controlled, phase 3 HELIOS trial in patients with previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL).
Ferreri and colleagues reported results of a phase 2 trial that evaluated single-drug maintenance therapy with the oral immunomodulatory drug lenalidomide as an alternative to intensified consolidation in patients with chemosensitive relapsed diffuse large B-cell lymphoma (DLBCL) who cannot be treated with consolidative transplantation.
Results of the subgroup analysis that assessed the treatment effect of ibrutinib versus temsirolimus on lymphoma symptoms in the phase 3, randomized RAY (MCL3001) trial of patients with relapsed and/or refractory mantle-cell lymphoma were reported.
Researchers reported updated results of the 3-arm randomized CLL11 study that evaluated the novel anti-CD20 monoclonal antibody obinutuzumab plus chlorambucil therapy versus chlorambucil alone in treatment-naive patients with chronic lymphocytic leukemia (CLL) and comorbidities.
The patient-reported health-related quality-of-life (HRQoL) data from the phase 3 GADOLIN trial of obinutuzumab (GA101) plus bendamustine versus bendamustine alone in CD20+ rituximab-refractory patients with indolent non-Hodgkin lymphoma were reported.
Researchers presented subgroup analysis data based on relevant high-risk prognostic factors of the randomized, double-blind, placebo-controlled, phase 3 HELIOS trial that evaluated ibrutinib plus bendamustine/rituximab (BR) therapy versus BR in patients with previously treated chronic lymphocytic leukemia.
Page 2 of 2
Results 11 - 20 of 20
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology